Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MOLN NASDAQ:NVCT NASDAQ:RVPH NASDAQ:THTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMOLNMolecular Partners$3.63-1.8%$3.73$3.36▼$6.90$146.72M1.092,062 shs4,100 shsNVCTNuvectis Pharma$6.11+1.6%$6.26$4.44▼$11.80$155.42M-0.29129,866 shs47,659 shsRVPHReviva Pharmaceuticals$0.62+10.0%$0.48$0.25▼$4.28$43.48M-0.083.76 million shs7.45 million shsTHTXTheratechnologies$3.42+0.9%$3.33$1.12▼$3.40$157.21M0.51735,945 shs3.27 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMOLNMolecular Partners-3.13%-6.04%-5.06%-11.08%-37.13%NVCTNuvectis Pharma+1.52%-1.31%+0.17%-22.75%-29.29%RVPHReviva Pharmaceuticals+28.48%-3.42%+97.74%+20.36%-52.31%THTXTheratechnologies0.00%0.00%+3.29%+7.85%+167.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMOLNMolecular Partners$3.63-1.8%$3.73$3.36▼$6.90$146.72M1.092,062 shs4,100 shsNVCTNuvectis Pharma$6.11+1.6%$6.26$4.44▼$11.80$155.42M-0.29129,866 shs47,659 shsRVPHReviva Pharmaceuticals$0.62+10.0%$0.48$0.25▼$4.28$43.48M-0.083.76 million shs7.45 million shsTHTXTheratechnologies$3.42+0.9%$3.33$1.12▼$3.40$157.21M0.51735,945 shs3.27 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMOLNMolecular Partners-3.13%-6.04%-5.06%-11.08%-37.13%NVCTNuvectis Pharma+1.52%-1.31%+0.17%-22.75%-29.29%RVPHReviva Pharmaceuticals+28.48%-3.42%+97.74%+20.36%-52.31%THTXTheratechnologies0.00%0.00%+3.29%+7.85%+167.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMOLNMolecular Partners 2.00Hold$8.00120.14% UpsideNVCTNuvectis Pharma 2.50Moderate Buy$15.33151.16% UpsideRVPHReviva Pharmaceuticals 2.78Moderate Buy$4.86678.39% UpsideTHTXTheratechnologies 2.33HoldN/AN/ACurrent Analyst Ratings BreakdownLatest RVPH, MOLN, THTX, and NVCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025MOLNMolecular PartnersWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NVCTNuvectis PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025RVPHReviva PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/29/2025RVPHReviva PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$2.009/27/2025MOLNMolecular PartnersWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025NVCTNuvectis PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025RVPHReviva PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025THTXTheratechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/19/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.009/15/2025RVPHReviva PharmaceuticalsBenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSpeculative Buy$14.00 ➝ $7.009/3/2025MOLNMolecular PartnersJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$4.50 ➝ $4.00(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMOLNMolecular Partners$681K215.45N/AN/A$3.99 per share0.91NVCTNuvectis PharmaN/AN/AN/AN/A$0.50 per shareN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ATHTXTheratechnologies$84.38M1.86N/AN/A($0.55) per share-6.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMOLNMolecular Partners-$61.39M-$2.08N/AN/AN/AN/A-50.66%-45.13%10/30/2025 (Estimated)NVCTNuvectis Pharma-$19M-$1.17N/AN/AN/AN/A-150.81%-94.84%11/4/2025 (Estimated)RVPHReviva Pharmaceuticals-$29.92M-$0.65N/AN/AN/AN/AN/A-259.17%11/13/2025 (Estimated)THTXTheratechnologies-$8.31M-$0.19N/A48.84N/A-10.85%N/A-9.83%N/ALatest RVPH, MOLN, THTX, and NVCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025RVPHReviva Pharmaceuticals-$0.12N/AN/AN/AN/AN/A11/4/2025Q3 2025NVCTNuvectis Pharma-$0.24N/AN/AN/AN/AN/A10/30/2025Q3 2025MOLNMolecular Partners-$0.53N/AN/AN/AN/AN/A8/25/2025H1 2025MOLNMolecular Partners-$0.53-$0.67-$0.14-$0.67N/AN/A8/14/2025Q2 2025RVPHReviva Pharmaceuticals-$0.15-$0.12+$0.03-$0.12N/AN/A8/5/2025Q2 2025NVCTNuvectis Pharma-$0.25-$0.30-$0.05-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMOLNMolecular PartnersN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMOLNMolecular PartnersN/A9.359.35NVCTNuvectis PharmaN/A2.662.66RVPHReviva PharmaceuticalsN/A0.900.90THTXTheratechnologiesN/A0.840.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMOLNMolecular Partners26.55%NVCTNuvectis Pharma96.77%RVPHReviva Pharmaceuticals63.18%THTXTheratechnologiesN/AInsider OwnershipCompanyInsider OwnershipMOLNMolecular Partners5.93%NVCTNuvectis Pharma30.52%RVPHReviva Pharmaceuticals27.18%THTXTheratechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMOLNMolecular Partners18040.38 million37.98 millionNot OptionableNVCTNuvectis Pharma825.46 million17.69 millionNot OptionableRVPHReviva Pharmaceuticals569.34 million50.49 millionOptionableTHTXTheratechnologies14045.98 millionN/AOptionableRVPH, MOLN, THTX, and NVCT HeadlinesRecent News About These CompaniesTheratechnologies Announces Completion of Acquisition by Future PakSeptember 25, 2025 | globenewswire.comTheratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future PakSeptember 16, 2025 | financialpost.comFTheratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future PakSeptember 16, 2025 | globenewswire.comTheratechnologies shareholders approve proposed acquisition by Future PakSeptember 12, 2025 | msn.comTheratechnologies Shareholders Approve Acquisition by Future Pak AffiliateSeptember 12, 2025 | tipranks.comTheratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future PakSeptember 12, 2025 | financialpost.comFTheratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future PakSeptember 12, 2025 | globenewswire.comTheratechnologies announces availability of EGRIFTA WRSeptember 6, 2025 | msn.comTheratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and LipodystrophySeptember 5, 2025 | globenewswire.comTheratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future PakSeptember 2, 2025 | globenewswire.comTheratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future PakAugust 18, 2025 | globenewswire.comTheratechnologies Reports Financial Results for the Second Quarter 2025July 9, 2025 | globenewswire.comTheratechnologies: Beyond GLP-1s - Is Tesamorelin's Exit A Sign Of New Metabolic Opportunities?July 7, 2025 | seekingalpha.comFuture Pak to buy Theratechnologies for $254 millionJuly 4, 2025 | thepharmaletter.comTTheratechnologies Stock (NASDAQ:THTX), Insider Trading ActivityJuly 3, 2025 | benzinga.comTheratechnologies Inc. (THTX) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comTheratechnologies Stock Short Interest Report | NASDAQ:THTX - BenzingaJuly 3, 2025 | benzinga.comTheratechnologies shareholders should take the deal, Research Capital saysJuly 3, 2025 | cantechletter.comCTheratechnologies to be bought by CB Biotechnology for $254MJuly 3, 2025 | msn.comTheratechnologies to Announce Second Quarter 2025 Financial ResultsJuly 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRVPH, MOLN, THTX, and NVCT Company DescriptionsMolecular Partners NASDAQ:MOLN$3.63 -0.07 (-1.78%) As of 10:07 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Nuvectis Pharma NASDAQ:NVCT$6.10 +0.10 (+1.58%) As of 10:18 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Reviva Pharmaceuticals NASDAQ:RVPH$0.62 +0.05 (+8.72%) As of 10:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.Theratechnologies NASDAQ:THTX$3.42 +0.03 (+0.86%) Closing price 09/25/2025Extended Trading$3.42 0.00 (0.00%) As of 09/25/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
